Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy

Journal of Nephrology

Volumn 27, Issue 1, 2014, Pages 103-106

  Hartono, Choli ^a,b   Chung, Miriam ^a,b   Kuo, Sheng F ^c   Seshan, Surya V ^b   Muthukumar, Thangamani ^a,b  

^a ROGOSIN INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK HOSPITAL QUEENS   (United States)

Author keywords

Bortezomib; Membranous nephropathy; Nephrotic syndrome; Proteasome inhibitor

Indexed keywords

ALBUMIN; BORTEZOMIB; CREATININE; PREDNISONE; RAMIPRIL; BORONIC ACID DERIVATIVE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; NEPHROTIC SYNDROME; PROTEINURIA; COMPLICATION; GLOMERULONEPHRITIS, MEMBRANOUS;

BORONIC ACIDS; BORTEZOMIB; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MIDDLE AGED; NEPHROTIC SYNDROME; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84896913221     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-013-0028-x     Document Type: Article

References (13)

1. Ponticelli C, Glassock RJ (2013) Glomerular diseases: membranous nephropathy-a modern view. Clin J Am Soc Nephrol. doi:10.2215/CJN.04160413
2. Polanco N, Gutierrez E, Covarsi A et al (2010) Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21(4):697-704
3. Cattran DC, Pei Y, Greenwood CM et al (1997) Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 51:901-907
4. Kidney Disease Improving Global Outcomes (2012) KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int 2:139-172
5. Beck LH, Bonegio RGB, Lambeau G et al (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11-21
6. Murtas C, Bruschi M, Candiano G et al (2012) Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 7:1394-1400
7. Ponticelli C, Zucchelli P, Passerini P et al (1989) A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320:8-13
8. Howman A, Chapman TL, Langdon MM et al (2013) Immunosuppression for progressive membranous nephropathy: a UK randomized controlled trial. Lancet 381:744-751
9. Shortt J, Oh DH, Opat SS (2013) ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 368:90-92
10. Forslund T, Sikio A, Anttinen J (2007) IgA nephropathy in a patient with IgG lambda light-chain plasmacytoma: a rare coincidence. Nephrol Dial Transplant 22:2705-2708
11. Ruggenenti P, Cravedi P, Chianca A et al (2012) Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23:1416-1425
12. Perry DK, Burns JM, Pollinger HS et al (2009) Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 9(1):201-209
13. Beck LH Jr, Fervenza FC, Beck DM et al (2011) Rituximabinduced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22:1543-1550